Return to content in this issue

 

Covid-19 vaccine tolerabilty in a patient with a delayed allergic reaction to polyethylene glycol: a case report

Loli-Ausejo D1,2, Gómez-Armayones S3,4, Sáez-Peñataro J4,5, González-Matamala MF1, Mascaró B1, Muñoz-Cano R1,2,4,6, Bartra J1,2,4,6


1Department of Allergy, Hospital Clínic de Barcelona, University of Barcelona. Barcelona, Spain.
2Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS). Barcelona, Spain.
3Department of Dermatology, Hospital Clínic de Barcelona, University of Barcelona. Barcelona, Spain.
4Technical Committee for Pharmacovigilance, Hospital Clínic de Barcelona. Barcelona, Spain.
5Department of Clinical Pharmacology, Medicines Division, Hospital Clínic de Barcelona, University of Barcelona. Barcelona, Spain.
6Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Red de Enfermedades Inflamatorias. Instituto de Salud Carlos III. Madrid, Spain.

J Investig Allergol Clin Immunol 2023; Vol. 33(3)
doi: 10.18176/jiaci.0843

Key words: COVID-19, COVID-19 vaccine, Polyethylene glycols, Vaccine excipients, Hypersensitivity